

1 **Supplemental Material for:**

2 **Introducing a new host for biotechnology: Genetic tool development for the**  
3 **thermotolerant *Bacillus coagulans***

4 Ákos T. Kovács, Mariska van Hartskamp, Oscar P. Kuipers, Richard van Kranenburg

5

6 **SUPPLEMENTARY MATERIALS AND METHODS**

7 **Bacterial strains and media.** *B. coagulans* strains were routinely grown in rich  
8 BC medium (9) at 45°C (genetic engineering) or 50°C (sporulation tests; LacZ cultures),  
9 at 120 rpm (for aerated cultures). For anaerobic growth BC broth was supplemented with  
10 1% glucose. Sporulation medium (SM) contains per liter: 8 g nutrient broth, 2 g  
11 (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub>, 3.5 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 10 g Bis-Tris, 0.12 g MgSO<sub>4</sub> · 7 H<sub>2</sub>O, 1 g KCl, 0.164 g  
12 Ca(NO<sub>3</sub>)<sub>2</sub> · 4 H<sub>2</sub>O, 1.25 mg MnCl<sub>2</sub> · 4 H<sub>2</sub>O, 0.15 mg FeSO<sub>4</sub>, pH 6.7.

13 **Transformation.** The electroporation protocol for *B. coagulans* DSM 1 (for  
14 pNZ124, pNZ8048, and pNW33n derivatives) is a modified protocol from that described  
15 elsewhere (9). *B. coagulans* DSM 1 was grown overnight at 45°C in 10 ml BC medium in  
16 a 100 ml bottle, without shaking. 100 ml BC medium in a 1 l bottle was inoculated with  
17 the overnight culture to a turbidity at 600 nm of 0.05 and incubated at 45°C, 120 rpm,  
18 until a turbidity of 0.45-0.65 was reached (approximately 3 hours). Cells were pelleted at  
19 4 °C, washed three times with ice-cold SG medium (50 ml, 25 ml, and 12.5 ml,  
20 respectively), resuspended in 200 µl ice-cold SG medium and used immediately for  
21 electroporation. Seventy-five microliters of cell suspension was mixed with 1 µg of  
22 plasmid DNA in an ice-cold electroporation cuvette (1 mm gap) and kept on ice for 2  
23 min. The electroporation settings using a Bio-Rad electroporator were 1.5 kV, 25 µF and

24 600Ω. Immediately after electroporation, cells were transferred to 1.3 ml of pre-warmed  
25 (45°C) RG medium and incubated for 3 h in an Eppendorf Thermomixer at 600 rpm.  
26 During the last hour antibiotic resistance was induced by addition of sublethal  
27 concentrations of appropriate antibiotics (0.025 mg·l<sup>-1</sup> tetracycline or 0.2 mg·l<sup>-1</sup>  
28 chloramphenicol). Cells were spread on BC plates containing the appropriate antibiotic  
29 and incubated at 45°C for 1-3 days.

30 **Construction of Δ*sigF* and Δ*lacZ* strains.** For deletion of the *sigF* gene, the  
31 upstream and downstream regions required for double crossover recombination were  
32 cloned into the integration vector pMH77. Vector pMH77 is based on the lactococcal  
33 cloning vector pNZ124 (7) and has a thermosensitive replicon in *B. coagulans* (9). The  
34 *cat* gene of pNZ124 was modified to contain an NcoI site overlapping the *cat* start codon,  
35 resulting in pMH3 (9). The pMH3 SalI-NcoI fragment containing the *cat* promoter was  
36 replaced by a synthetic SalI-NcoI fragment containing a *B. coagulans* promoter  
37 (GU323910). The resulting plasmid was designated pMH71. To enable multiple use of  
38 the *Cre-lox* system, *lox66* and *lox71* sites (4,5) flanking the promoter-*cat* region were  
39 introduced by PCR using primers P1 and P2 (sequences of oligonucleotides are presented  
40 in Supplementary Table 1) with pMH71 as template. The resulting PCR product was  
41 digested with BglII-SalI and used to exchange with the BglII-SalI promoter-*cat* region of  
42 pMH71, resulting in plasmid pMH77. The *sigF* upstream and downstream regions were  
43 generated by PCR using primers P3 and P4 or P5 and P6, respectively, with DSM 1  
44 chromosomal DNA as a template. The *sigF*-upstream PCR product was cloned as SalI-  
45 NheI fragment in pMH77. Subsequently, the *sigF*-downstream PCR product was cloned  
46 as EcoRI-XhoI fragment. The resulting integration plasmid was designated pMH79. The

47 integrity of the sequences of the upstream and downstream regions was confirmed by  
48 sequencing.

49 For the use of the *Cre-lox* system, the *cre* gene was cloned into a pNZ124  
50 derivative containing *tetK*. First, the *tetK* gene was amplified by PCR using primers P7  
51 and P8 and pGhost8:ISS1 as template (6) and cloned as SalI-BglII fragment into pNZ124  
52 replacing the *cat* gene. Then the *cre* gene was cloned on a HindIII-EcoRI fragment from  
53 pNZ5347 (4), resulting in plasmid pMH66.

54 For deletion of the *lacZ* gene, the flanking recombination regions were obtained  
55 by PCR using oligonucleotides P11 and P12 (upstream) and P13 and P14 (downstream),  
56 digested with SacI and PstI (blunted), and SnaBI and BamHI (blunted), respectively, and  
57 cloned into the SacI-PvuII sites of pMH77, resulting in integration plasmid pLAC.

58 For integration, a colony harboring the integration plasmid was cultured overnight  
59 at 45°C, after which the temperature was shifted to 60°C and incubation was continued  
60 for 1.5 hours. A dilution series was plated on BC plates containing chloramphenicol and  
61 incubated overnight at 60°C. Single colonies were tested for double crossover  
62 recombination by PCR analysis. For removal of the *cat* gene using the *Cre-lox* system,  
63 the double crossover strain was transformed with pMH66 using electroporation. Cells  
64 were plated on BC plates containing tetracycline. Transformants were tested for the  
65 absence of *cat* by PCR analysis, and the pMH66 plasmid was cured by incubation at  
66 60°C. Deletions were confirmed by sequence analysis.

67 In the case of the *lacZ* mutant, single crossover recombinants were selected on BC  
68 plates containing chloramphenicol and incubated overnight at 60°C. After successive  
69 inoculation of single crossover recombinants in the absence of chloramphenicol, cells  
70 were plated on BC plates containing 60 mg·l<sup>-1</sup> X-gal (5-bromo-4-chloro-3-indolyl-β-D-

71 galactopyranoside). A double-crossover white colony was selected that showed  
72 chloramphenicol sensitivity and deletion of *lacZ* gene was verified by sequence analysis.

73

74 **Sporulation test.** 100 µl of a culture grown for 18 hours in SM medium was  
75 incubated at 80°C for 30 min and plated on BC plates. Samples were also assayed for  
76 viable cell number using colony counts without heat treatment.

77

78 **Construction of reporter plasmids.** The *B. coagulans lacZ* gene was PCR-  
79 amplified with P15 and P16, digested with NcoI and BamHI and cloned into the NcoI-  
80 BglII sites of pNZ8048 (3), resulting in pNZlac. Amplifications of promoter regions were  
81 done with oligonucleotides P17 and P18 (*spoIIAA*), P19 and P20 (*dacF*), P21 and P22  
82 (*cotE*), P23 and P24 (*spoIID*), P25 and P26 (*pta*), P27 and P28 (*ldhL*), P29 and P30 (*pgi*)  
83 PCR fragments were digested with NcoI and XbaI enzymes and inserted of corresponding  
84 sites of pNZlac (see Table 1). In all cases where PCR was involved, the sequences were  
85 checked by sequencing.

86

87 **Construction of D-lactate dehydrogenase plasmid.** A *B. coagulans* ATCC  
88 23498 genomic fragment encoding amylase gene promoter ( $P_{amy}$ ) activity (8) was  
89 produced as a synthetic DNA fragment introducing an NcoI site overlapping the *amy* start  
90 codon and flanking BglII and BamHI sites (see Figure S1). The fragment was cloned in  
91 pGEM-T Easy (Promega) and sequenced. *Lactobacillus delbrueckii* subsp. *bulgaricus*  
92 LMG 6901 (BCCM/LMG, Gent, Belgium) was grown at 37°C in MRS broth (Difco).  
93 The *L. bulgaricus* LMG 6901 *ldhA* gene encoding an D-lactate dehydrogenase (1) was

94 generated by PCR using primers P9 and P10. The PCR product was cloned as a blunt-  
95 XbaI fragment into pUC18 digested with XbaI-SmaI and its integrity was confirmed by  
96 nucleotide sequence analysis. Subsequently, P<sub>amy</sub>, as BglIII-NcoI fragment, and the *ldhA*  
97 gene, as RcaI-PstI fragment, were cloned into pNW33n digested with BglIII-PstI. The  
98 resulting plasmid, pJS27, has the *ldhA* gene of *L. bulgaricus* translationally fused to the  
99 *B. coagulans* ATCC 23498 P<sub>amy</sub>.

100

101 **Fermentations and analytical procedures.** Batch fermentations were performed  
102 in a bioreactor (3 l Applikon ®) with 1 l of BC broth without Bis-Tris buffer and  
103 supplemented with 30 or 50 g·l<sup>-1</sup> glucose as described previously (9). Organic acids  
104 (formic acid, acetic acid, propionic acid, butyric acid, pyruvic acid, lactic acid, 2-hydroxy  
105 butyric acid, glycolic acid, oxalic acid, sorbic acid, fumaric acid, succinic acid, benzoic  
106 acid, maleic acid, malic acid, citric acid) were measured after (trans)-esterification to  
107 their corresponding methyl-ester using a proton donor. Due to this esterification to the  
108 methyl-esters, the results are the sum of the concentrations of the acids present in the  
109 free-, ester- and salt-form. Hexanoic acid was added as an internal standard and the  
110 samples were assayed using a GLC equipped with two capillary columns with a different  
111 polarity coupled to two flame ionization detectors using similar settings as described  
112 elsewhere (2). Identification of the components was based on the two retention times  
113 obtained. D- and L-lactates were methylated to methyl-lactate and measured by head-  
114 space analysis on a chiral column. Peak areas of the D-lactate and L-lactate peaks were  
115 used to calculate the relative contribution of each enantiomer to the chiral purity.

116

117 **FIG. S1.** Nucleotide sequence of synthetic DNA fragment containing the *B. coagulans*  
118 ATCC 23498 P<sub>amy</sub> (position -289 to -3, (8)) flanked by BglII and NcoI-BamHI sites  
119 (underlined). The ATG start codon of the *amy* gene in the NcoI site is printed boldface.

120

121 1 AGATCTTGGT TCCCCACCTT TTTTACAGAC TTATCACTAT ATTATTATAG  
122 51 ATAAACCGGC CAAACAACCA AATCGGGGCG CAAAGGAGAG CCGGGGCGTG  
123 101 GATTTAAACC ATTTTTGGAA AAACAAAAGG AAAACCTGCT TGTA AAAAGA  
124 151 TGTTTTCGCG AAACGAAAGC GGGAATAGTA CCTTTGTTCT CTCGCCTTT  
125 201 TGTCATGCTT AAAATCATAA TTGATTGAAA ATTTTTTCAT GTTCACTTAT  
126 251 ACTAAACGCA TCAACTATTA CTTCTTTTGG AAGGGGCAGT TTCC**ATG**GGG  
127 301 ATCC

128

129

130 **TABLE S1.** Oligonucleotide primers used in this study.

131

Oligonucleotide	gene	RES <sup>a</sup> introduced	Sequence <sup>b</sup>
P1	<i>lox66</i>	SalI, NheI	<u>CCC</u> GT <u>CGACGCTAGCT</u> ACCGTTCGTATAATGTATGC TATACGAAGTTATGTGGATAAGACAACAGGATTTCG
P2	<i>lox71</i>	BglII	CGC <u>AGATCTT</u> ACCGTTCGTATAGCATAACATTATACG AAGTTATCCTTCTTCAACTAACGGGGCAGGTTAG
P3	$\Delta$ <i>sigF</i>	SalI	<u>CCC</u> GT <u>CGACGTTGCC</u> GACAAAACAGTCAAAC
P4	$\Delta$ <i>sigF</i>	NheI	<u>CCC</u> GCTAGCCGGCACGACTCCTTAATTGC
P5	$\Delta$ <i>sigF</i>	EcoRI	CGCGAATTCAAATACTTGAAGTGATGAAAGAGCGC
P6	$\Delta$ <i>sigF</i>	XhoI	<u>CCGCTCGAGTGAAT</u> CGTTCCGTCCTGGAC
P7	<i>tetK</i>	SalI	<u>CCGGT</u> CGACACAAAATATAAGAATTTGATAAAAAGA AATTTCCG
P8	<i>tetK</i>	BglII	GCCAGATCTGAGCTCTGCGAGGCTTAAACC
P9	<i>ldhA</i>	RcaI	GACAATTCATGACTAAAATTTTTGC
P10	<i>ldhA</i>	XbaI, PstI	GGATTTCTCTAGACTGCAGTTAGCCAACCTTAA
P11	<i>lacZ</i>	-	TGCAACCGTGTCCAGAGTTCTGAAT
P12	<i>lacZ</i>	-	CGTCCTTGTCAACCGGAAGCGAATC
P13	<i>lacZ</i>	-	GGGTCCGTCCGTAATGCCTATCAA
P14	<i>lacZ</i>	-	TGCGGCTTGGCGTGGATAAATCCTG
P15	<i>lacZ</i>	NcoI	GAGCCATGGACTTGGAGGAATGCGTGAT
P16	<i>lacZ</i>	-	AACACGCAAACAGACCGTAG
P17	<i>spoIIAA</i>	XbaI	GAGTCTAGAAAGTAAAACGCGCAGGCTGGT
P18	<i>spoIIAA</i>	NcoI	ACGCCATGGGCCTCCTTCGCTGTTAATA
P19	<i>dacF</i>	XbaI	GAGTCTAGATATGCGAAATCCATCCAAG
P20	<i>dacF</i>	NcoI	ACGCCATGGAACTTGTAATAATCGTAAAAC
P21	<i>cotE</i>	XbaI	GAGTCTAGATTCTTCCGGCACCCCTCCAC
P22	<i>cotE</i>	NcoI	ACGCCATGGTCCCTCATCTATTTTCAATTC
P23	<i>spoIID</i>	XbaI	GAGTCTAGAGAAAGGGTTCGACGACGAAG
P24	<i>spoIID</i>	NcoI	ACGCCATGGTGATCGAAGTGGTGGAAAG
P25	<i>pta</i>	XbaI	GAGTCTAGATTGCCGGAATCTTTTCACAG
P26	<i>pta</i>	NcoI	ACGCCATGGACTCCTCGTATAACGGTATC
P27	<i>ldhL</i>	XbaI	GAGTCTAGAAAGCCTCATCGCCGTTTCCC
P28	<i>ldhL</i>	NcoI	ACGCCATGGATCTTCCTCCCATCAAAG
P29	<i>pgi</i>	XbaI	GAGTCTAGAGCTCCCGACCGCGTTAAATG
P30	<i>pgi</i>	NcoI	ACGCCATGGAGCCGGTAAATCATTGCC

<sup>a</sup>RES denotes restriction endonuclease site.

<sup>b</sup>Introduced RES underlined in sequence.

132

133 **TABLE S2.**  $\beta$ -galactosidase activity in  $\Delta lacZ$  and  $\Delta lacZ\Delta sigF$  strains. Cells were  
 134 collected from overnight cultures for the measurements. Data are averages of 6 biological  
 135 replicates.  
 136

Plasmid	$\beta$ -galactosidase activity	
	<i>B. coagulans</i>	<i>B. coagulans</i>
	$\Delta lacZ$	$\Delta lacZ\Delta sigF$
Sporulation genes		
pSPOIIA-LAC	580 $\pm$ 100	520 $\pm$ 60
pSPOIID-LAC	240 $\pm$ 40	11 $\pm$ 3
pDACF-LAC	46 $\pm$ 23	3.5 $\pm$ 0.3
pCOTE-LAC	560 $\pm$ 60	10.4 $\pm$ 4.1
Metabolic genes		
pPTA-LAC	570 $\pm$ 44	540 $\pm$ 61
pLDH-LAC	450 $\pm$ 48	410 $\pm$ 38
pPGI-LAC	18.1 $\pm$ 4.9	14.7 $\pm$ 5.5

137



138 **REFERENCE LIST**

139

- 140 1. **Bernard, N., T. Ferain, D. Garmyn, P. Hols, and J. Delcour.** 1991. Cloning of  
141 the D-lactate dehydrogenase gene from *Lactobacillus delbrueckii* subsp. *bulgaricus*  
142 by complementation in *Escherichia coli*. FEBS Lett. **290**:61-64.
- 143 2. **Braunegg, G., B. Sonnleitner, and R. M. Lafferty.** 1978. Rapid gas-  
144 chromatographic method for determination of poly- $\beta$ -hydroxybutyric acid in  
145 microbial biomass. Eur. J. Appl. Microbiol. Biotechnol. **6**:29-37.
- 146 3. **Kuipers, O. P., P. G. de Ruyter, M. Kleerebezem, and W. M. de Vos.** 1998.  
147 Quorum sensing-controlled gene expression in lactic acid bacteria. J. Biotechnol.  
148 **64**:15-21.
- 149 4. **Lambert, J. M., R. S. Bongers, and M. Kleerebezem.** 2007. Cre-*lox*-based system  
150 for multiple gene deletions and selectable-marker removal in *Lactobacillus*  
151 *plantarum*. Appl. Environ. Microbiol. **73**:1126-1135.
- 152 5. **Langer, S. J., A. P. Ghafouri, M. Byrd, and L. Leinwand.** 2002. A genetic screen  
153 identifies novel non-compatible *loxP* sites. Nucleic Acids Res. **30**:3067-3077.
- 154 6. **Maguin, E., H. Prevost, S. D. Ehrlich, and A. Gruss.** 1996. Efficient insertional  
155 mutagenesis in *lactococci* and other gram-positive bacteria. J. Bacteriol. **178**:931-  
156 935.
- 157 7. **Platteuw, C., G. Simons, and W. M. de Vos.** 1994. Use of the *Escherichia coli*  $\beta$ -  
158 glucuronidase (*gusA*) gene as a reporter gene for analyzing promoters in lactic acid  
159 bacteria. Appl. Environ. Microbiol. **60**:587-593.
- 160 8. **Sloma, A., N. M. Hannet, M. A. Stephens, C. F. Rudolph, G. A. Rufo, and J.**  
161 **Pero.** 1992. Expression of heterologous DNA using the *Bacillus coagulans* amylase  
162 gene. US patent 5171673.
- 163 9. **van Kranenburg, R., M. van Hartskamp, E. A. J. Heintz, E. J. G. van**  
164 **Mullekom, and J. Snelders.** 2007. Genetic modification of homolactic  
165 thermophilic *Bacilli*. PCT WO2007/085443 .  
166  
167